Breaking ground in CMT1B treatment: AAV9-mediated dual RNAi and gene replacement therapy targeting schwann cells improves myelination and peripheral nerve function in mice

被引：0
|
作者：
McCulloch, M. [1 ,2 ]
Munezero, D. [1 ]
Paripati, A. [1 ]
Zhu, J. [1 ]
Chermahini, G. Amini [1 ]
Chuah, R. [1 ]
Rashnonejad, A. [1 ,2 ,3 ]
机构：
[1] Nationwide Childrens Hosp, Ctr Gene Therapy, Columbus, OH USA
[2] Ohio State Univ, Mol Cellular & Dev Biol Grad Program, Columbus, OH USA
[3] Ohio State Univ, Dept Pediat, Columbus, OH USA
来源：
NEUROMUSCULAR DISORDERS | 2024年 / 43卷
关键词：
D O I：
10.1016/j.nmd.2024.07.417
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
180
引用
收藏
页数：1
相关论文
共 6 条
  • [1] Breaking Ground in CMT1B Treatment: AAV9-Mediated Dual RNAi and Gene Replacement Therapy Targeting Schwann Cells Improves Myelination and Peripheral Nerve Function in Mice
    Munezero, Daniella
    Zhu, Jingting
    Paripati, Arun
    Chuah, Russell
    Taylor, Lauren
    Rashnonejad, Afrooz
    MOLECULAR THERAPY, 2024, 32 (04) : 10 - 10
  • [2] AAV9-mediated SH3TC2 gene replacement therapy targeted to Schwann cells for the treatment of CMT4C
    Georgiou, Elena
    Kagiava, Alexia
    Sargiannidou, Irene
    Schiza, Natasa
    Stavrou, Marina
    Richter, Jan
    Tryfonos, Christina
    Zetterberg, Henrik
    Heslegrave, Amanda
    Christodoulou, Christina
    Kleopa, Kleopas A.
    MOLECULAR THERAPY, 2023, 31 (11) : 3290 - 3307
  • [3] Efficacy & Safety of AAV9-Mediated GDAP1 Gene Replacement Therapy in CMT4A Mice
    Sanli, Merve Emecen
    Dong, Thomas
    Jiji, Anjala
    Hu, Yuhui
    Gray, Steven J.
    Chen, Xin
    MOLECULAR THERAPY, 2024, 32 (04) : 781 - 782
  • [4] Endogenous Human SMN1 Promoter-driven Gene Replacement Improves the Efficacy and Safety of AAV9-mediated Gene Therapy for SMA in mice
    Xie, J.
    Xie, Q.
    Ma, H.
    Chen, X.
    Zhu, Y.
    Ma, Y.
    Jalinous, L.
    Su, Q.
    Tai, P.
    Gao, G.
    NEUROMUSCULAR DISORDERS, 2022, 32
  • [5] Endogenous human SMN1 promoter-driven gene replacement improves the efficacy and safety of AAV9-mediated gene therapy for spinal muscular atrophy (SMA) in mice
    Xie, Q.
    Ma, H.
    Chen, X.
    Zhu, Y.
    Ma, Y.
    Jalinous, L.
    Su, Q.
    Tai, P.
    Gao, G.
    Xie, J.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A20 - A21
  • [6] Endogenous Human SMN1 Promoter-Driven Gene Replacement Improves the Efficacy and Safety of AAV9-Mediated Gene Therapy for Spinal Muscular Atrophy (SMA) in Mice
    Xie, Qing
    Ma, Hong
    Chen, Xiupeng
    Zhu, Yunxiang
    Ma, Yijie
    Jalinous, Leila
    Su, Qin
    Tai, Phillip
    Gao, Guangping
    Xie, Jun
    MOLECULAR THERAPY, 2022, 30 (04) : 127 - 128
1